Eisai Co., Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Haruo Naito
- Full Time Employees
- 11,092
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 4-6-10, Koishikawa Tokyo Japan 112-8088
- IPO Date
- Dec 1, 1995
- Website
- eisai.co.jp
- Similar Companies
- Business
- Eisai Co., Ltd. (TSE:4523; OTC:ESALY) is a research-based pharmaceutical company that discovers, develops and markets prescription medicines focused primarily on neurology and oncology. Founded in 1941 and headquartered in Tokyo, Japan, the company operates globally through manufacturing sites in Japan, the United States, China, Indonesia, Taiwan, India and the United Kingdom, with marketing subsidiaries in more than 30 countries across Asia, Europe, North America and other regions. Eisai's main products include LEQEMBI (lecanemab), a monoclonal antibody for early Alzheimer's disease approved in 48 countries including the United States, European Union, Japan and China; LENVIMA (lenvatinib), an oral tyrosine kinase inhibitor approved in over 80 countries for thyroid cancer, hepatocellular carcinoma, renal cell carcinoma and endometrial carcinoma, often in combination with pembrolizumab; Dayvigo (lemborexant), an orexin receptor antagonist for insomnia approved in over 25 countries including the United States and Japan; Fycompa (perampanel), a selective AMPA receptor antagonist for partial-onset and primary generalized tonic-clonic seizures approved in over 75 countries; as well as other therapies such as Aciphex/Pariet (rabeprazole) for gastroesophageal reflux disease and Aricept (donepezil) for Alzheimer's disease. In recent developments, Eisai entered a strategic research collaboration with SEED Therapeutics in August 2024 to discover molecular glue degraders for neurodegeneration and cancer targets, with potential milestone payments up to $1.5 billion and led a $24 million Series A-3 financing for SEED; expanded its Canadian operations with a major headquarters upgrade in Mississauga in June 2025, increasing staff by 246% since 2020 to over 100 employees; divested European and UK rights to Targretin (bexarotene) to H.A.C. Pharma in January 2025; and in August 2025 transferred U.S. commercial rights to Fycompa while advancing global approvals for products like URECE (dotinurad) in China for gout.
Eisai (OTCMKTS:ESALY) Share Price Crosses Below 50 Day Moving Average – Here’s Why
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
President Trump demands drugmakers slash prices within 60 days
Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug
Eisai Co Ltd (ESALF) Q1 2025 Earnings Call Transcript
Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
Shares of Japan's Eisai tumble after EU rejects Alzheimer's drug
Eisai will seek re-examination of CHMP opinion för lecanemab
EU medicines regulator rejects Eisai-Biogen Alzheimer's drug
Dassault Systèmes: Eisai Selects Medidata's Clinical Data Studio to Enhance and Modernize Clinical Trial Efficiency and Patient Experience
Eisai: Margin Of Safety From Very Modest Penetration Expectations
Japan's Eisai developing dementia drug for US market, Nikkei reports
Eisai and Biogen launch Alzheimer's drug Leqembi in China
FDA accepts filing of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's Disease
FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
FDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Eisai Co Ltd. (ESALF) Q4 2024 Earnings Call Transcript